Immunovia AB (FRA:1YR)
€ 0.0338 0.0013 (4%) Market Cap: 8.99 Mil Enterprise Value: 6.59 Mil PE Ratio: 0 PB Ratio: 2.83 GF Score: 42/100

Q1 2021 Immunovia AB (publ) Earnings Call Transcript

Apr 28, 2021 / 02:30PM GMT
Release Date Price: €6.25 (-2.39%)
Operator

Hello, and welcome to Immunovia Q1 report for 2021. (Operator Instructions)

Today, I am pleased to present Patrik Dahlen, CEO. Please begin your meeting.

Patrik Dahlen;publ;CEO
Immunovia AB

()-

Thank you very much. Good afternoon, everyone. Thank you for joining us today, and thank you for your continued interest in Immunovia. My name is Patrik Dahlen. I am the CEO of Immunovia, and I will be presenting the quarter 1 2021 results for Immunovia.

Next page, Page 2. Here, you can read our disclaimers and forward-looking statements, and I encourage you to read these at your leisure.

If I could have the next page, please, Page 3. Today's agenda is as follows: I will start by discussing the importance of early detection of pancreatic cancer. Second, I will give you a summary of the Q1 highlights. Here, I will review the blind validation study and the optimization study that were presented in Q1. Thirdly, I will touch upon the road to reimbursement and reiterate how we see that process going forward. Next, I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot